AI biology

What is Chai Discovery?

AI foundation-model company for molecular structure prediction and drug discovery.

Category
AI biology
Headquarters
San Francisco, California
Founded
2024
Employees
Private; early-stage research team
Total funding
Undisclosed public funding
Status
Private

What is Chai Discovery?

Chai Discovery is a ai biology company headquartered in San Francisco, California.

Chai Discovery develops AI models for molecular structure prediction and drug discovery, including the Chai-1 model for biomolecular structures. The company serves researchers and drug-discovery teams through model access and partnerships; customer counts are not public.

The company was founded in 2024 and remains private. Its public profile is strongest around Chai-1 and Molecular modeling, while detailed revenue figures are not publicly disclosed.

As of June 2026, the safest public read is that Chai Discovery is scaling through enterprise partnerships and capital-intensive product development rather than a self-serve consumer motion.

What does Chai Discovery offer?

Chai Discovery's public product set centers on Chai-1, Molecular modeling, Drug-discovery partnerships.

  • Chai-1· Structure prediction
  • Molecular modeling· AI biology
  • Drug-discovery partnerships· R&D
  • Research model access· Platform

How does Chai Discovery make money?

Research platform and partnership model; public enterprise pricing is not disclosed.

Research platform and partnership model; public enterprise pricing is not disclosed. No public list pricing; model/API and partnership terms are not public.

Growth is driven by enterprise adoption, strategic partnerships, and proof that the platform can deliver measurable operational, clinical, scientific, or mission outcomes. Because Chai Discovery does not publish standard list prices, buyers should treat budget sizing as a custom-contract exercise.

The commercial motion therefore depends on executive sponsorship, security and compliance review, and evidence that the product can integrate into existing workflows rather than replace them all at once.

Who leads Chai Discovery?

Chai Discovery is led by Joshua Meier, Co-founder and CEO.

  • Joshua MeierCo-founder and CEOCo-founder · since 2024Former OpenAI and Meta AI researcher leading the company.
  • Jack DentCo-founderCo-founderAI biology researcher.
  • OpenAI Startup FundInvestor/backerLaunch investorBacked the company's early work.

How do you contact Chai Discovery's leadership?

Public contact route; no verified personal email pattern found. Use the listed public company route rather than guessed personal inboxes.

Email formatPublic contact route; no verified personal email pattern found

    How much funding has Chai Discovery raised?

    Chai Discovery has undisclosed public funding and is private.

    2024: Launch / seed — Undisclosed, led/backed by Thrive Capital, OpenAI Startup Fund and others reported (Valuation undisclosed).

    The latest public valuation/status marker is Undisclosed. Where a valuation is undisclosed, public reporting only supports the financing amount and participating investors.

    Funding is best interpreted as capacity for product build-out, hiring, regulatory or deployment work, and longer sales cycles; it should not be read as proof of profitability unless the company has separately disclosed profitability.

    How did Chai Discovery get here?

    Chai Discovery's timeline runs from its 2024 founding through major financing and product milestones.

    1. 2024FoundedChai Discovery launched as an AI biology startup.
    2. 2024Chai-1 releasedThe company introduced Chai-1 for biomolecular structure prediction.
    3. 2024Open model accessChai made research artifacts available to the scientific community.
    4. 2025Drug-discovery attentionInvestors and healthcare analysts cited Chai as a promising AI biology company.
    5. 2026Private build-outPublic funding and customer metrics remained limited.

    Who are Chai Discovery's competitors?

    Chai Discovery competes with specialized startups and larger platform companies in ai biology.

    • Isomorphic LabsAI drug design backed by Alphabet.
    • EvolutionaryScaleProtein language models and ESM3.
    • CradleProtein engineering AI software.
    • Iambic TherapeuticsAI small-molecule discovery.

    Chai Discovery — frequently asked questions

    Agent CTA Background

    Revenue work. On autopilot.

    Start Free TrialBuilt for revenue teams who care about quality.